The concentrations of tumor necrosis factor (TNF) produced by human peripheral blood mononuclear cells (MNC) were measured using a radioimmunoassay (RIA) for human TNF. This was developed using a rabbit antiserum against human recombinant TNF (Hu rTNF), and Hu rTNF labeled with Na125l by a modification of the chloramine T method. This RIA does not detect human lymphotoxin, interleukin-1 alpha or beta, interleukin 2, interleukin 6, interferon alpha or gamma, granulocyte-macrophage-colony stimulating factor, and C5a des arg. A good correlation (r = 0.89) was found between the RIA and the cytolytic bioassay for TNF. The sensitivity of the RIA is between 3 and 78 pg/ml (median 11 pg/ml).
INTRODUCTION
Tumor necrosis factor-alpha (TNF, synonym cachectin) is a cytokine with a wide variety of actions [l ] . A number of activities of the molecule are shared with another cytokine, interleukin-1 (IL) (a and 0). For in stance the pyrogenic effect; the ability to induce an acutephase response; and the stimulatory effects on fibro blasts, osteoclasts, endothelial, and synovial cells are common to both molecules [2] [3] [4] . Recent studies also indicate that there is a strong synergism between TN F and IL-1 0 [5] , and it has become apparent that TN F stimulates the production of IL-1 both in vivo and in vitro [2] .
Measurement of T N F in culture supernatant has fo cused on the cytotoxicity assay. However, IL-1 and other © 1988 Alan R. Liss, Inc.
substances that are often present with TN F in cell super natants affect the T N F cytotoxicity assay, since IL-l also exhibits cytotoxic properties [6] . In the present paper we have employed a radioimmunoassay (RIA) for TN F se creted by human mononuclear cells in vitro under a variety of conditions. Furthermore, we compare the con centrations of T N F to IL-l 0 and IL-1 a using endotoxin (lipopolysaccharide, LPS) as a stimulus.
TNF-a In Vitro

MATERIALS AND METHODS
Preparation of the Antiserum
Female New Zealand white rabbits (Pine Acres, Bur lington, VT) were immunized with 50 ¿ig recombinant human tumor necrosis factor (Hu rTNF), obtained from three sources: Genentech Inc. (South San Francisco, CA), Cetus Corp. (Emeryville, CA), and Biogen (Cambridge, MA). The initial immunization took place in complete Freund's adjuvant, using 12 intradermal injections. After 8 weeks the animals were boosted monthly with 50 ¿ig TNF in incomplete Freunds's adjuvant intramuscularly. Unfractionated serum was used as anti-TNF antiserum. Cross-reactivity of this antiserum with human recombi nant interleukin-1 ß (Cistron Technology Inc., Pine Brook, NJ), human recombinant interleukin-1 a (kindly provided by Dr Alan Shaw, Biogen, Geneva, Switzer land), human recombinant interleukin-2 (Cetus Corp.), human recombinant interleukin-6 (Genetic Institute, Cambridge, MA), human recombinant interferon alpha (Schering Corp., Kenilworth, NJ), human recombinant interferon gamma (Schering Corp.), human recombinant granulocyte-macrophage-colony stimulating factor (Ge netics Institute, Cambridge, MA), human C5a des arg (kindly provided by Dr KB Yancey, Uniformed Services University of the Health Sciences, Bethesda, MD), hu man recombinant lymphotoxin, and murine recombinant TNF (both kindly provided by Dr MA Palladino Jr, Genentech, Inc.) was investigated in various concentra tions in the radioimmunoassay as described below.
Radiolabeling Hu rTNF
Hu rTNF was labeled using a modification of the chloramine T method [7] ; 5 ¿¿g Hu rTNF (500 /zg/ml) and 0.5 mCi N a,2:>l (100 mCi/ml, New England Nuclear, Boston, MA) were added to 10 ¿¿1 of 0.5 M sodium phosphate buffer (pH 7.4) and mixed. Next, 10 ¿¿g chlor amine T (Sigma Chemical Co, St Louis, MO; 2.5 mg/ml in 0.25 M sodium phosphate buffer, pH 7.4) were added and mixed by gently pipetting for exactly 10 s. The reaction was terminated by adding 100 pig of the reducing agent sodium metabisulfite (Sigma; 5 mg/ml in 0.25 M sodium phosphate buffer, pH 7.4). Finally, 300 ¡jl 1 of BSA-buffer containing 0.01 M phosphate buffered sa line, 0.25% bovine serum albumin (BSA, Sigma), and 0.05% sodium azide) was added. The radiolabeled ma terial was chromatographed on a Sephadex G50 (fine) (Pharmacia, Piscataway, NJ) column (0.8 x 30 cm) to separate the radiolabeled protein from the free 1251. BSAbuffer was used to equilibrate and to run the column. Twenty-five fractions of 0.7 ml were collected. The radioactivity of aliquots of these fractions was deter mined in a gamma counter. Next, small aliquots from each fraction were incubated with a 1:100 dilution of the anti-TNF antiserum for 18 h at room temperature, and then precipitated with 6 % (w/v) polyethylene glycol 8000 (Fisher Scientific Company, Fair Lawn, NJ) and 1 % sheep antirabbit IgG (Sigma).
The homogeneity of the radiolabeled TNF was deter mined with SDS-polyacrylamide gel electrophoresis (17%) [8] and autoradiography. The biological activity of the radiolabeled TNF was measured in the bioassay for TNF (see below). The specific activity of the labeled TNF was calculated assuming 75% recovery and using the known efficiency of the gamma counter.
Titration of Anti-TNF Antiserum
Aliquots of the radiolabeled TNF containing 15,000 cpm were diluted in 100 /¿I BSA-buffer and incubated with serial twofold dilutions of the anti-TNF antiserum for 18 h at room temperature, and then precipitated with an equal volume of 6 % polyethylene glycol and 1% sheep antirabbit IgG.
Radioimmunoassay for TNF
Both standards and samples were assayed in duplicate or in some experiments in triplicate in 10 x 75-mm polystyrene tubes (Stockwell Scientific, Walnut, CA). In every assay, 12 standards of Hu rTNF (5,000, 2,500, 1,250, 625, 313, 157, 79, 40, 20, 10, 5, and 0 pg/ml) were employed. Depending on the nature of the samples, the standards were diluted in either human serum, urine, or BSA-buffer. On the first day of the assay, 100 ¿¿1 of the anti-TNF antiserum (diluted in order to precipitate 40% of the radiolabeled TNF) was added to 100 /xl of the standards or to 100 /xl of the samples. To determine the nonspecific binding (NSB), 100 /¿I BSA-buffer was added to a standard containing no TNF. On the same day, 300 Ijl 1 of BSA-buffer containing 0.3% heat-inactivated nor mal rabbit serum was added to each tube. After vortexing, the tubes were incubated at room temperature. The next day, 100 /zl of BSA-buffer containing 10,000 cpm of radiolabeled TNF were added to each tube, and after vortexing, again incubated at room temperature. On the third day, 700 ¿¿1 of BSA-buffer containing 9% of poly ethylene glycol 8000 and 1.4% sheep antirabbit IgG were added. The tubes were vortexed and then centrifuged at l,500g for 15 min. Thereafter, the supernatants were decanted, and the tubes were kept inverted and allowed to dry for at least 15 min before being counted. The mean cpm of duplicate or triplicate standards were calculated and the counts of the NSB subtracted. All standards were then expressed as a percentage of the standard containing no TNF (zero standard). The values obtained were con verted using the logit transformation, according to the formula logit x = ln(x/100 -x). The logit values were plotted on the x-axis against the concentrations on a logarithmic y-axis. An exponential curve fit was per formed, using Cricket graph (Cricket Software, Philadel phia, PA) on an Apple Macintosh Plus computer. The formula for the curve fit obtained was used to calculate the "backfit" of the standard curve and to determine the concentration of TNF in samples. Values < 95% of the zero standard (logit x < 2.94) were accepted.
Radioimmunoassays for IL-1 a and ¡3
Radioimmunoassays for human IL-1 (3 [9] and a [10] were performed as described.
Bioassay for TNF
To measure the TNF activity in a bioassay, standards and samples were incubated with L929 cells (ATCC search Triangle Park, NC) was added. Cultures were performed either with or without 0.5 fig/ml indomethacin (Sigma). After 24 h of culture at 37°C in a watersaturated atmosphere with 5% C 0 2, either the culture supernatants or the contents of each well after three freeze-thaw cycles were harvested, centrifuged at 10,000g (Micro centrifuge, Fisher Scientific), for 1 min and fro zen at -70°C until assay.
Hu rTNF in Mice
TNF concentrations were measured in EDTA-treated CCL1) as described by Flick and Gifford [11] . In short, plasma obtained by cardiac puncture at various time the L929 cells were cultured in RPMI 1640 containing 2 mM L-glutamine and 10% heat-inactivated fetal calf serum (all from microbiological Associates, Walkersville, MD) in 75-cnr polystyrene tissue culture flasks (Falcon, Oxnard, CA) and split every 3 days. One day after subculture, the nonadherent cells were decanted after vigorous shaking of flask. After adding fresh me dium the adherent cells w'ere scraped with a policeman (Costar, Cambridge, MA), and after washing (450g, 10 min), 100-^1 aliquots of the cell suspension (5 x 105/ml) were pippetted in 94 wells of a 96-well flat-bottom microtiterplate (A/S Nunc, Roskilde, Denmark). After incubation overnight (37°C, 5% C 0 2), the culture super natants were decanted, and 100 /¿I of 15 /xg/ml actinomycin D (Sigma) in saline, and 100 fi\ of RPMI 1640 with 10% fetal calf serum w'as added to each w'ell. After adding 100 /xl of either medium (control), TNF standards or samples to at least quadruplicate wells, the plates were reincubated. The next day, the supernatants w'ere de canted and the wells were rinsed with saline. After stain ing of the cells w'ith 0.1 % (w/v) crystal violet (Sigma) in 100% methanol for 20 min, the plates were rinsed with tap water and dried. Absorbance (A) was measured in an ELISA reader at 595 nm and the percentage of cytotox icity determined as 
Isolation and Culture of Human Mononuclear Cells
Heparinized blood (10 U heparin/ml blood) from hu man volunteers was diluted threefold in 0.15 M saline and centrifuged on pyrogen-free Ficoll Hypaque. The mononuclear cells (MNC) of the interphase were washed three times in ultrafiltered [ 12] 
Measurement of TNF Concentration in Human Plasma
Plasma samples prepared from either citrated or hepa rinized blood from patients with febrile illnesses were tested for TNF in the RIA.
RESULTS
Validation and Specificity of the RIA for Human TNF
As shown in Figure 1 , fractions of radiolabeled Hu rTNF w'hich had the highest binding to anti-TNF were found in the first peak of eluting radioactivity, whereas the second peak contained the nonprecipitable free io dine. The fractions with greater than 85% of precipitable radiolabel were pooled and used as radiolabeled TNF in the RIA. The specific activity of this pool was approxi- (Fig. 2, insert) . The bio logical activity of the Hu rTNF appeared not to have been affected by the labeling procedure (Fig. 2) .
Titration of the antiserum with the pooled radiolabeled ligand is shown in Figure 3 . A 41% precipitation with polyethylene glycol/anti rabbit IgG at an anti-TNF dilu tion of 1:20,000 was detected and this dilution was cho sen for use in the subsequent RIAs.
Representative standard curves for TNF in BSA-buffer and frozen-thawed human serum are shown in Figure 4 . The standard curves in these fluids do not coincide, which implies that standard curves should be generated not only in BSA-buffer, but also in relevant biological fluids. From these standard curves it can be seen that the sensitivity of the assay is < 10 pg/ml (95% confidence limit, 2.9 logit). In more than 20 radioimmunoassays using radiolabeled TNF that was iodinated at different occasions, the sensitivity in BSA-buffer was in the same order of magnitude (between 3 and 78 pg/ml, median 11 pg/ml).
The RIA for Hu TNF did not show cross-reactivity with either 100 or 10 ng/ml human recombinant IL-1 ß; 
Measurement of TNF Concentrations in Human MNC Lysates and Supernatants
When supernatants from 24-h cultures of peripheral blood MNC, either unstimulated or stimulated, were tested in both the RIA and bioassay, a good correlation was found ( Fig. 5) . Because of the different detection ranges of both assays (bioassay, 500-15 pg/ml; RIA, 220 van der Meer et al was found: 2 ng/ml TNF with 1 ng/ml LPS up to 100 ng/ ml TNF with 50 ng/ml LPS, and thereafter leveling off.
The IL-1 (3 concentration in these supernatants measured in an RIA showed an increase from 0.2 ng/ml to 19 ng/ ml with the same concentrations of LPS. Concentrations of IL-1 a: increased from 0.04 to 1 ng/ml (Fig. 6 ).
To investigate the intraindividual consistency of TNF production, human MNC of three donors isolated and cultured on three different days were incubated with medium alone, medium with 1 ng/ml LPS, and medium with 30 fig!ml PHA. These experiments show good con sistency for unstimulated and LPS stimulated cells but less so far PHA stimulation (Fig. 7) . edly freezing and thaw'ing of the samples (up to three times) was found not to affect the results of the RIA.
Distribution of TNF Produced by MNC of a Cohort
Comparison of Amounts of TNF, IL-1 ¡3 and a Secreted by MNC
Next, the dose-effect relationship for LPS stimulation of peripheral blood MNC was assessed in supernatants from cells of three normal donors, cultured for 24 h (Fig.   6 ). A dose dependent increase of the TNF production The amount of TNF produced by human MNC in vitro was determined in a cohort of 50 normal volunteers (laboratory personnel). We studied total TNF production by measuring the combined supernatant and cell lysate material present after 24 h of incubation. The data are depicted in Figure 8 . With few exceptions, TNF levels were below the lower detection limit without exogenous stimuli. The unstimulated MNC show a narrow concen tration range of TNF. LPS-stimulation led to TNF con centrations up to nearly 6 ng/ml (median 2.0 ng/ml). In (Fig. 8 ). The differences in TNF production in the presence of indomethacin were not significant for the unstimulated cells; however, for both LPS-and PHAstimulated cells, indomethacin significantly increased the amount of TNF (p < 0.005, Wilcoxon matched-pairs signed-ranks, two-tailed). The MNC preparations after Ficoll Hypaque separa tion contained on average 19.1 % (SD ± 10.7) mono cytes. No correlation was found between the number of monocytes and the amount of TNF produced (data not shown).
Use of the RIA With Plasma Samples
To investigate whether we could recover TNF from the circulation, we injected mice with Flu rTNF intraperitoneally, and detected the appearance and clearance of Hu rTNF in the plasma. An injection of 2 ¿xg of human TNF, which is a nonlethal dose, produced a peak concentration of 266 ng/ml after 12 min. After 15 min, the concentra tion had fallen to 127 ng/ml.
When plasma samples (with heparin or citrate) from patients with a variety of febrile illnesses (burns, septi cemia, Still's disease, Hodgkin's disease) were added directly to the RIA, TNF was not detected. We observed that in the presence of these acute-phase samples, precipitable radioactivity was often greater than 100% of the zero standard, suggesting enhanced binding of the radio label, even if the standard curves for these assays were performed in normal plasma. However, in heparinized plasma samples of four patients with malaria, we were able to detect TNF concentrations of 274 + SEM 45 pg/ ml.
DISCUSSION
Employing the modified chloramine T method of ra diolabeling and selecting the highest binding fractions to the specific polyclonal anti-TNF, we report the develop ment of a sensitive and useful RIA. The process of radiolabeling of the TNF molecule does not degrade the molecule as demonstrated by SDS-polyacrylamide gel electrophoresis, nor does it affect the bioactivity. Al though we have found a good correlation between the RIA and the bioassay for TNF, the RIA is clearly supe rior to the bioassay. The latter is more laborious and less specific than the RIA. Substances inhibiting or promoting growth or adherence of the L929 cells may lead to falsepositive or false-negative results. Also factors, such as IL-1/5, may synergize with TNF and lead to increased cytotoxicity (Ikejima et al, unpublished results).
The RIA is particularly useful for the detection of TNF produced by cultured human monocytes and natural killer cells [13] [14] [15] . Using a solid-phase RIA for TNF, Cuturi et al recently reported that T lymphocytes exposed to phorbol esters or calcium ionophore also produce TNF [15] . For studies like ours, in which lymphocytes are not separated from monocytes, it is important to know that the RIA does not detect the comparable lymphocyte prod uct, lymphotoxin (TNF j3), despite its structural homol ogy with TNF (TNF a) [16, 17] . In the experiments using PHA as a stimulant, production of lymphotoxin could be expected to have occurred [15, 18] . The concentrations of TNF produced in the cultures of the unstimulated human cells in our experiments show a narrow range, owing to strict measures to eliminate con taminating bacterial products (such as LPS) from re agents and culture media [12] . Incubation with indomethacin showed a slight but significant increase in the amount of TNF produced by LPS-or PHA-stimulated 222 van der Meer et al cells, pointing to an inhibitory effect of products of the cyclooxygenase pathway.
Using the R IA s to TNF, IL-1 o: and (3, we measured the concentrations of these three major cytokines secreted by human MNC stimulated w'ith various doses of LPS. In a highly consistent fashion, the cells of the three donors secreted large amounts of TNF and a tenfold lesser amount of IL-1 (3. The amount of IL-1 a secreted was considerably low^er. If, however, total (ie., secreted and cell-associated) IL-1 ¡3 is compared with total TNF, the amount of IL-1 (3 is greater than the amount TNF (Endres et al, unpublished data). The explanation should be sought in differences in the molecular structure of TNF and IL-1. TNF has a prominent signal peptide for cleavage and transport [ 16] , and thus the amount of TNF secreted approximates the total amount of TNF pro duced. IL-1 is lacking a clear signal peptide [19] , and this results in a variable amount of extracellular IL-1 [20] . Since LPS only stimulates TNF production from monocytes and not from T cells [ 15] , it can be calculated from the numbers of monocyte that stimulation with LPS results in the secretion of up to 0.2 pg of TNF per monocyte in 24 h.
The experiments using the cells of 50 different healthy donors demonstrate the normal distribution pattern of TNF production in vitro. With LPS as a stimulant, the cells of 10% of the donors produce less than 0.5 ng/ml TNF, and the cells of most donors produce more than 1 ng/ml. With PH A, even higher concentrations of TNF are found. It is conceivable that the greater amount of TNF produced upon stimulation w'ith PHA is mediated via an effect on the lymphocyte. We have not been able to correlate the amount of TNF produced to obvious characteristics such as sex, race, and age. Since these studies were performed over a period of 6 weeks, sea sonal influences can also be ruled out. The experiments performed to investigate the intra-individual consistency of TNF production suggest that high and low responders with regard to TNF production exist. Since the gene for TNF is closely located to the genes for HLA [21] , the linkage of HLA haplotypes to TNF production should be investigated.
The results of the experiments in which Hu rTNF was injected into mice suggest a slightly shorter half-life of human TNF than the 10-min half-life found by Flick and Gifford with murine TNF [22] . Detection of TNF in the circulation of patients is still a problem when plasma or serum samples are put directly in the RIA. Similar prob lems have been reported by Scuderi et al [23] , who were also unable to detect TNF in the majority of patients with infectious or neoplastic disease. Like them, we detected circulating TNF in malaria. The detectability of TNF in mice injected with human recombinant IL-1 and the ob servation that acute-phase plasma samples bind more than 100% of the radiolabeled TNF points to substances in the circulation of humans with various diseases that compete with anti-TNF for binding of the labeled TNF Studies are under way to separate TNF from such sub stances. However, the RIA is highly useful to measure TNF in stimulated MNC from humans, eg, in disease states, on drugs, and during cytokine treatment. At a more basic level, detection of immunoreactive TNF in studies on cytokine interaction, and studies of how var ious agents affect TNF synthesis and gene expression in vitro will help to clarify our understanding of the control of TNF production.
